Lumen HomepageTechnologyPipelinePress
 
The PolyArginine Treated vEiN grafTs (PATENT) study was Lumen's first clinical study
This Lumen sponsored clinical study was a placebo-controlled, double-blinded, and randomized Phase I/IIA study performed at Toronto General Hospital (TGH)
TGH is home to the largest open-heart surgery center in Canada and has the best clinical study outcomes of cardiovascular surgery in the country
Study Design: Patients requiring multiple-vein CABG had comparative treatment of LT-1951 and placebo.
Phase I Study successfully completed
Phase II Study – 20 patients treated and evaluated
Clear signal (P < 0.01) for treatment reducing the rate of graft failure at 1 month
Need for vehicle optimization identified
© 2005-2010 Lumen Therapeutics   |   All rights reserved.   |